65,437 trials
Metastatic Pancreatic Adenocarcinoma
Primary: Number of Patients Who Experienced a Dose-Limiting Toxicity (DLT) — 9; 8 participants
Epilepsy
Primary: Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 84.4 Percentage of participants
Cocaine Dependence · Alcohol Dependence
Primary: Cocaine Craving as Measured on the Visual Analog Scale (VAS) 1 — 19; 48 units on a scale — p=0.08
Epilepsy
Primary: Percentage of Participants With at Least One Adverse Event Reported Spontaneously by the Participant/or Caregiver (Including Parent/Legal Guardian) or Observed by the…
Peripheral Artery Disease · Atherosclerosis · Artery Diseases, Peripheral
Primary: Number of Participants With Primary Lesion Patency — 194; 57; 43 Participants — p=0.0017
Aortic Stenosis · Symptomatic Aortic Stenosis · Aortic Regurgitation
Primary: All-cause Mortality — 0 Participants
Heterozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline to Week 24 in LDL-C — -6.23; -44.53 percent change — p=< 0.0001
Infantile Refsum's Disease · Zellweger Syndrome · Adrenoleukodystrophy
Primary: Number of Participants With Excretion of Atypical Bile Acids in Urine by Category — 10; 51; 11; 9 Participants
Heavy Uterine Bleeding · Uterine Fibroids
Primary: Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL) — 213.70; 269.36; 321.73; 335.11 mL — p=< 0.001
Acute Gouty Arthritis
Primary: Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS — -26.1…
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids — 3.5; -19.8; -25.4; -25.7 percent change — p=0.0012
Cachexia
Primary: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) — 3.0; 2.1; -2.1; 3.1 Millimeters of mercury
Spinal Cord Injury · Quadriplegia
Primary: Enrolled Subjects Achieve Clinically Acceptable Tidal Volume Sustained Over a Continuous 4 Hour Period. — 52; 1 Participants — p=<0.001
Hepatocellular Carcinoma
Primary: Median Overall Survival (OS) Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular…
Body Dysmorphic Disorder · Obsessive-Compulsive Spectrum Disorder · Anxiety Disorders
Primary: Body Dysmorphic Disorder Symptoms (as Measured by the BDD-YBOCS) — 32.21; 31.49; 26.92; 27.27 score on a scale — p=<.01